If they don't raise at a good valuation, then there won't be any IPO and there won't be any deal. So far, there's no raise and I don't think that's because they can't. If they do raise at a good valuation, dilution will be minimal, even after the IPO is done.
Still, I think strong chance we're in for a surprise and the guidance from January is simply background information.
(3)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links